Jenni Kononoff

Jenni Kononoff

Auto-generated profile, based on publicly available information

Jenni Kononoff

MSD Finland Oy, Global Medical & Scientific Affairs, Espoo, Finland

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MKMarsida Kallupi
Marsida Kallupi
LCLieselot L. G. Carrette
Lieselot L. G. Carrette
JKJenni Kononoff
Jenni Kononoff
LWLeah C. Solberg Woods
Leah C. Solberg Woods
APAbraham A. Palmer
Abraham A. Palmer
GGGiordano De Guglielmo
Giordano De Guglielmo
Significance: More than 2 million individuals in the United States currently have a substance use disorder that is related to prescription opioid pain relievers. We identified individual differences in oxycodone addiction-like behaviors in outbred heterogenous stock rats with high and low addiction-like behaviors. We found that the downregulation of nociceptin levels in the central nucleus of the amygdala (CeA) may be responsible for hyper–γ-aminobutyric acid (GABA)ergic tone in the CeA that is observed in individuals who develop addiction-like behaviors. The development of small molecules that target the nociceptin system may have therapeutic efficacy for the treatment of opioid use disorder.

29 February 2020 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
AKAdam Kimbrough
Adam Kimbrough
JKJenni Kononoff
Jenni Kononoff
SSSierra Simpson
Sierra Simpson
MKMarsida Kallupi
Marsida Kallupi
SSSharona Sedighim
Sharona Sedighim
OGOlivier George
Olivier George

1 May 2018 in eneuro
Verified
Journal Article
Open access
PDF file
JKJenni Kononoff
Jenni Kononoff
MKMarsida Kallupi
Marsida Kallupi
AKAdam Kimbrough
Adam Kimbrough
DCDana Conlisk
Dana Conlisk
GGGiordano De Guglielmo
Giordano De Guglielmo
OGOlivier George
Olivier George
GPR139 is an orphan G protein-coupled receptor (GPCR) that is expressed mainly in the brain, with the highest expression in the medial habenula. The modulation of GPR139 receptor function has been hypothesized to be beneficial in the treatment of some mental disorders, but behavioral studies have not yet provided causal evidence of the role of GPR139 in brain dysfunction. Because of the high expression of GPR139 in the habenula, a critical brain region in addiction, we hypothesized that GPR139 may play role in alcohol dependence. Thus, we tested the effect of GPR139 receptor activation using the selective, brain-penetrant receptor agonist JNJ-63533054 on addiction-like behaviors in alcohol-dependent male rats. Systemic administration of JNJ-63533054 (30 mg/kg but not 10 mg/kg, p.o.) reversed the escalation of alcohol self-administration in alcohol-dependent rats, without affecting water or saccharin intake in dependent rats or alcohol intake in nondependent rats. Moreover, systemic JNJ-63533054 administration decreased withdrawal-induced hyperalgesia, without affecting somatic signs of alcohol withdrawal. Further analysis demonstrated that JNJ-63533054 was effective only in a subgroup of dependent rats that exhibited compulsive-like alcohol drinking. Finally, site-specific microinjection of JNJ-63533054 in the habenula but not interpeduncular nucleus (IPN) reduced both alcohol self-administration and withdrawal-induced hyperalgesia in dependent rats. These results provide robust preclinical evidence that GPR139 receptor activation reverses key addiction-like behaviors in dependent animals, suggest that GPR139 may be a novel target for the treatment of alcohol use disorder, and demonstrate that GPR139 is functionally relevant in regulating mammalian behavior.

23 August 2017 in Alcohol, Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
AKAdam Kimbrough
Adam Kimbrough
GGGiordano De Guglielmo
Giordano De Guglielmo
JKJenni Kononoff
Jenni Kononoff
MKMarsida Kallupi
Marsida Kallupi
EZEric P. Zorrilla
Eric P. Zorrilla
OGOlivier George
Olivier George

1 September 2017 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
GGGiordano De Guglielmo
Giordano De Guglielmo
AMAlessandra Matzeu
Alessandra Matzeu
JKJenni Kononoff
Jenni Kononoff
JMJulia Mattioni
Julia Mattioni
RMRémi Martin-Fardon
Rémi Martin-Fardon
OGOlivier George
Olivier George
Cebranopadol is a novel agonist of nociceptin/orphanin FQ peptide (NOP) and opioid receptors with analgesic properties that is being evaluated in clinical Phase 2 and Phase 3 trials for the treatment of chronic and acute pain. Recent evidence indicates that the combination of opioid and NOP receptor agonism may be a new treatment strategy for cocaine addiction. We sought to extend these findings by examining the effects of cebranopadol on cocaine self-administration (0.5 mg/kg/infusion) and cocaine conditioned reinstatement in rats with extended access to cocaine. Oral administration of cebranopadol (0, 25, and 50 μg/kg) reversed the escalation of cocaine self-administration in rats that were given extended (6 hour) access to cocaine, whereas it did not affect the self-administration of sweetened condensed milk (SCM). Cebranopadol induced conditioned place preference but did not affect locomotor activity during the conditioning sessions. Finally, cebranopadol blocked the conditioned reinstatement of cocaine seeking. These results show that oral cebranopadol treatment prevented addiction-like behaviors (i.e., the escalation of intake and reinstatement), suggesting that it may be a novel strategy for the treatment of cocaine use disorder. However, the conditioned place preference that was observed after cebranopadol administration suggests that this compound may have some intrinsic rewarding effects.

1 May 2016 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Open access
PDF file
JVJenni Kononoff Vanhanen
Jenni Kononoff Vanhanen
SNSaara Nuutinen
Saara Nuutinen
MTMervi Tuominen
Mervi Tuominen
PPPertti Panula
Pertti Panula
The brain histamine system has been implicated in regulation of sensorimotor gating deficits and in Gilles de la Tourette syndrome (GTS). Histamine also regulates alcohol reward and consumption via H3 receptor (H3R), possibly through an interaction with the brain dopaminergic system. Here we identified the histaminergic mechanism of sensorimotor gating and the role of histamine H3R in the regulation of dopaminergic signaling. We found that H3R knockout mice displayed impaired prepulse inhibition (PPI) indicating deficiency in sensorimotor gating. H1R knockout and HDC knockout mice had similar PPI as their controls. Dopaminergic drugs increased PPI of H3R knockout mice to the same level as in control mice suggesting that changes in dopamine receptors might underlie deficient PPI response when H3R is lacking. Striatal D1R mRNA level was lower and D1 and D2 receptor-mediated activation of extracellular signal-regulated kinase 1/2 (ERK1/2) was absent in the striatum of H3R knockout mice suggesting that H3R is essential for the dopamine receptor-mediated signaling. In conclusion, these findings demonstrate that H3R is an important regulator of sensorimotor gating and the lack of H3R significantly modifies striatal dopaminergic signaling. These data support the usefulness of H3R ligands in neuropsychiatric disorders with pre-attentional deficits and disturbances in dopaminergic signaling.